These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 26366797)

  • 1. Treatment of the genitourinary syndrome of menopause.
    Palacios S; Mejía A; Neyro JL
    Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genitourinary Syndrome of Menopause.
    Shifren JL
    Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
    Eder SE
    Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
    McLendon AN; Clinard VB; Woodis CB
    Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's new in the world of postmenopausal sex?
    Iglesia CB
    Curr Opin Obstet Gynecol; 2016 Oct; 28(5):449-54. PubMed ID: 27517339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
    Reid RL; Black D; Derzko C; Portman D
    J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genitourinary syndrome of the menopause--dawn of a new era?
    Panay N
    Climacteric; 2015; 18 Suppl 1():13-7. PubMed ID: 26366795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
    Edwards D; Panay N
    Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMS - Consensus statement.
    Pitkin J;
    Post Reprod Health; 2018 Sep; 24(3):133-138. PubMed ID: 30244644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
    DeGregorio MW; Zerbe RL; Wurz GT
    Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of dyspareunia secondary to vulvovaginal atrophy.
    Fantasia HC
    Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on management of genitourinary syndrome of menopause: A practical guide.
    Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
    Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.
    Wallace SL; St Martin B; Lee K; Sokol ER
    Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
    Pinkerton JV; Kagan R
    Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
    Portman DJ; Gass ML;
    J Sex Med; 2014 Dec; 11(12):2865-72. PubMed ID: 25155380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
    Portman DJ; Gass ML;
    Menopause; 2014 Oct; 21(10):1063-8. PubMed ID: 25160739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
    Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
    Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Local estrogen therapy--clinical implications--2012 update].
    Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
    Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.